Genomic predictors and oncogenic drivers in hepatocellular carcinoma.
will optimise decision-making for liver cancer patients by identifying genomic prognostic determinants and oncogenic drivers.
core team comprises leading European researchers in the basic, translational and clinical fields of liver cancer.
is a 3-year translational research project which aims to solve core problems in the management of hepatocellular carcinoma (HCC), the third most common cause of cancer-related death worldwide.
The ‘Handbook of Translational Medicine’ is available now. Edited by Prof Josep M Llovet in collaboration with other teachers from the official Master in Translational Medicine (University of Barcelona).
Prof Llovet has been elected Vice-Chair of the AASLD Hepatobiliary Neoplasia SIG. His 2 year term will begin on January 1st, 2017 until December 31st, 2018 and then he will move into the Chair role for 2 years beginning January 1st, 2019 until December 31st, 2020.
Prof Josep M Llovet
Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, Poon RT, Zender L, Lowe SW, Hong W, Luk JM.
Berdasco M, Esteller M.
Gaujoux S, Pinson S, Gimenez-Roqueplo AP, Amar L, Ragazzon B, Launay P, Meatchi T, Libé R, Bertagna X, Audebourg A, Zucman-Rossi J, Tissier F, Bertherat J.
More scientific publications
Prof. Vincenzo Mazzaferro
Fondazione IRCCS Istituto Nazionale dei tumori (INT)
Project led by:
Copyright © 2010 - 2017 HEPTROMIC
HEPTROMIC is a project in the 'Health' Theme of the Specific Programme 'Cooperation' of the European Commission's Seventh Framework Programme.